SenzaGen
6.84 SEK +7.21%1 investor is following this company
Senzagen is a medical technology company. The company develops and carries out genomic in vitro tests, which means that the toxicological ability of various chemicals is not tested on animals but instead in test tubes. The company has developed a technological platform that is used to study the impact of substances produced by actors in the pharmaceutical, cosmetics, and chemical industries. Research and development take place from the head office in Lund.
Revenue
49.87M
EBIT %
-45.1 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
SENZA
Daily low / high price
6.52 / 6.94
SEK
Market cap
165.45M SEK
Turnover
189.9K SEK
Volume
28K
Latest videos
Financial calendar
General meeting
2024-05-15
Interim report
2024-05-15
Interim report
2024-08-15
Interim report
2024-11-08
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Carl Borrebaeck | 7.0 % | 7.0 % |
Malin Lindstedt | 6.7 % | 6.7 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
NOTICE OF ANNUAL GENERAL MEETING OF SENZAGEN AB (Publ)
SenzaGen’s chemical industry orders continue to increase
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools